A genetic variant in p63 (rs17506395) is associated with breast cancer susceptibility and prognosis

Gene

Volumn 535, Issue 2, 2014, Pages 170-176

  Zhang, Ning ^a   Huo, Qiang ^a   Wang, Xiaolong ^a   Chen, Xi ^a   Long, Li ^a   Guan, Xiao ^a   Jiang, Liyu ^a   Ma, Tingting ^a   Hu, Wenwei ^b   Yang, Qifeng ^a,c  

^a SHANDONG UNIVERSITY   (China)

^b RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^c Shandong Key Laboratory of Digital Human and Clinical Anatomy   (China)

Author keywords

Breast cancer; P63; Prognosis; Single nucleotide polymorphism; SNP; Susceptibility

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MESSENGER RNA; PROGESTERONE RECEPTOR; PROTEIN P63;

ADULT; ALLELE; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER PROGNOSIS; CANCER RISK; CANCER SUSCEPTIBILITY; CANCER TISSUE; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MIDDLE AGED; ONCOGENE; P63 GENE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM;

BREAST CANCER; ER; ESTROGEN RECEPTOR; HARDY-WEINBERG EQUILIBRIUM; HER2; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2; HWE; IHC; IMMUNOHISTOCHEMISTRY; P63; PCR; POLYMERASE CHAIN REACTION; PR; PROGESTERONE RECEPTOR; PROGNOSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISMS; SNP; SNPS; SUSCEPTIBILITY;

ADULT; AGED; ALLELES; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOTYPE; HUMANS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 84891163368     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2013.11.038     Document Type: Article

References (38)

1. Allocati N., Di Ilio C., De Laurenzi V. p63/p73 in the control of cell cycle and cell death. Exp. Cell Res. 2012, 318:1285-1290.
2. Athanasiu L., et al. Intron 12 in NTRK3 is associated with bipolar disorder. Psychiatry Res. 2011, 185:358-362.
3. Atwal G.S., et al. Haplotype structure and selection of the MDM2 oncogene in humans. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:4524-4529.
4. Atwal G.S., et al. Altered tumor formation and evolutionary selection of genetic variants in the human MDM4 oncogene. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:10236-10241.
5. Au N.H., et al. P63 expression in lung carcinoma: a tissue microarray study of 408 cases. Appl. Immunohistochem. Mol. Morphol. 2004, 12:240-247.
6. Bergholz J., Xiao Z.X. Role of p63 in development, tumorigenesis and cancer progression. Cancer Microenviron. 2012, 5:311-322.
7. Botstein D., Risch N. Discovering genotypes underlying human phenotypes: past successes for Mendelian disease, future approaches for complex disease. Nat. Genet. 2003, 33(Suppl.):228-237.
8. Carlson C.S., et al. Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am. J. Hum. Genet. 2004, 74:106-120.
9. Dhillon P.K., et al. Aberrant cytoplasmic expression of p63 and prostate cancer mortality. Cancer Epidemiol. Biomarkers Prev. 2009, 18:595-600.
10. Dupont W.D., Plummer W.D. Power and sample size calculations. A review and computer program. Control. Clin. Trials 1990, 11:116-128.
11. Dutt A., Beroukhim R. Single nucleotide polymorphism array analysis of cancer. Curr. Opin. Oncol. 2007, 19:43-49.
12. Erichsen H.C., Chanock S.J. SNPs in cancer research and treatment. Br. J. Cancer 2004, 90:747-751.
13. Feng Z., et al. Regulation of female reproduction by p53 and its family members. FASEB J. 2011, 25:2245-2255.
14. Garcia S., et al. Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and c-Met and with proteomic basal-like phenotype. Hum. Pathol. 2007, 38:830-841.
15. Graziano V., De Laurenzi V. Role of p63 in cancer development. Biochim. Biophys. Acta 2011, 1816:57-66.
16. Guan X., et al. Polymorphisms in the p63 and p73 genes are associated with ovarian cancer risk and clinicopathological variables. J. Exp. Clin. Cancer Res. 2012, 31:89.
17. Hanker L., et al. Clinical relevance of the putative stem cell marker p63 in breast cancer. Breast Cancer Res. Treat. 2010, 122:765-775.
18. Houlston R.S., Peto J. The search for low-penetrance cancer susceptibility alleles. Oncogene 2004, 23:6471-6476.
19. Hsiao Y.H., et al. Increased invasiveness and aggressiveness in breast epithelia with cytoplasmic p63 expression. Int. J. Biol. Sci. 2010, 6:428-442.
20. Hu W., Zheng T., Wang J. Regulation of fertility by the p53 family members. Genes Cancer 2011, 2:420-430.
21. Li X., et al. LAPTM4B allele *2 is associated with breast cancer susceptibility and prognosis. PLoS One 2012, 7:e44916.
22. Liu X., et al. Identification of novel variants of metadherin in breast cancer. PLoS One 2011, 6:e17582.
23. Marchini S., et al. DeltaNp63 expression is associated with poor survival in ovarian cancer. Ann. Oncol. 2008, 19:501-507.
24. Mavaddat N., Antoniou A.C., Easton D.F., Garcia-Closas M. Genetic susceptibility to breast cancer. Mol. Oncol. 2010, 4:174-191.
25. Nekulova M., Holcakova J., Coates P., Vojtesek B. The role of p63 in cancer, stem cells and cancer stem cells. Cell. Mol. Biol. Lett. 2011, 16:296-327.
26. Parsons J.K., Gage W.R., Nelson W.G., De Marzo A.M. p63 protein expression is rare in prostate adenocarcinoma: implications for cancer diagnosis and carcinogenesis. Urology 2001, 58:619-624.
27. Pelosi G., et al. p63 immunoreactivity in lung cancer: yet another player in the development of squamous cell carcinomas?. J. Pathol. 2002, 198:100-109.
28. Ribeiro-Silva A., Zambelli Ramalho L.N., Britto Garcia S., Zucoloto S. The relationship between p63 and p53 expression in normal and neoplastic breast tissue. Arch. Pathol. Lab. Med. 2003, 127:336-340.
29. Risch N.J. Searching for genetic determinants in the new millennium. Nature 2000, 405:847-856.
30. Risch N. The genetic epidemiology of cancer: interpreting family and twin studies and their implications for molecular genetic approaches. Cancer Epidemiol. Biomarkers Prev. 2001, 10:733-741.
31. Risch N., Merikangas K. The future of genetic studies of complex human diseases. Science 1996, 273:1516-1517.
32. Rodriguez S., Gaunt T.R., Day I.N. Hardy-Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies. Am. J. Epidemiol. 2009, 169:505-514.
33. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J. Clin. 2012, 62:10-29.
34. Sjakste T., Paramonova N., Grislis Z., Trapina I., Kairisa D. Analysis of the single-nucleotide polymorphism in the 5'UTR and part of intron I of the sheep MSTN gene. DNA Cell Biol. 2011, 30:433-444.
35. Tempfer C.B., Hefler L.A., Schneeberger C., Huber J.C. How valid is single nucleotide polymorphism (SNP) diagnosis for the individual risk assessment of breast cancer?. Gynecol. Endocrinol. 2006, 22:155-159.
36. Vanbokhoven H., Melino G., Candi E., Declercq W. p63, a story of mice and men. J. Invest. Dermatol. 2011, 131:1196-1207.
37. Weickert C.S., et al. Variants in the estrogen receptor alpha gene and its mRNA contribute to risk for schizophrenia. Hum. Mol. Genet. 2008, 17:2293-2309.
38. Yang Q., Moran M.S., Haffty B.G. Bcl-2 expression predicts local relapse for early-stage breast cancer receiving conserving surgery and radiotherapy. Breast Cancer Res. Treat. 2009, 115:343-348.